Amit Sachdev - 15 Nov 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Reporting relationship: EVP, Chief Patient Officer
Issuer ticker: VRTX
Reported as of: 15 Nov 2021
Net transaction value: -$9,547
SEC form: 4
Accepted by SEC: 16 Nov 2021, 15:07:33 UTC
Prior SEC filing: 19 May 2021
Next SEC filing: 03 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Sabrina Yohai, Attorney-in-Fact

Key filing fact

Amit Sachdev filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 16 Nov 2021.

Key facts

This page summarizes Amit Sachdev's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 16 Nov 2021, 15:07.

Change

Previous filing in this sequence was filed on 19 May 2021.
Current net transaction value: -$9,547.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRTX transaction

Common Stock

Sale

Transaction value: $3,922
Shares: -21
Change %: -0.07%
Price: $186.78
Shares after: 31,958
Date: 15 Nov 2021
Ownership: Direct
Footnotes: F1, F2, F3

VRTX transaction

Common Stock

Sale

Transaction value: $5,624
Shares: -30
Change %: -0.09%
Price: $187.48
Shares after: 31,928
Date: 15 Nov 2021
Ownership: Direct
Footnotes: F1, F3, F4

VRTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 882
Date: 15 Nov 2021
Ownership: 401(k)

VRTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 15,573
Date: 15 Nov 2021
Ownership: Held in Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.

Footnote F2

Open market sales reported on this line occurred at a weighted average price of $186.78 (range $186.22 to $187.19).

Footnote F3

Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Footnote F4

Open market sales reported on this line occurred at a weighted average price of $187.48 (range $187.24 to $187.85).